Research programme: non-nucleoside reverse transcriptase inhibitors - Tibotec

Drug Profile

Research programme: non-nucleoside reverse transcriptase inhibitors - Tibotec

Alternative Names: NNRTI research programme - Tibotec; Non-nucleoside reverse transcriptase inhibitors research programme - Tibotec

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tibotec BVBA
  • Class Pyridones
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in Belgium
  • 20 Feb 2008 This programme is still in active development
  • 10 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the Viral infections pharmacodynamics and antimicrobial section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top